Back to Database
DSIP
Delta Sleep-Inducing Peptide
Low Risk
Sleep & Wellness
A neuropeptide studied for sleep promotion. Early research showed delta-wave sleep effects, but the largest double-blind study concluded it is "not likely to be of major therapeutic benefit" for insomnia.
Benefits
May promote delta-wave (deep) sleep in some individuals
Modulates sleep/wake cycles without sedation
Analgesic (pain-reducing) effects in some studies
May enhance recovery during sleep
Side Effects & Risks
Fatigue if dose too highmild
Injection site irritationmild
Daytime grogginessmild
Headache (rare)mild
Dosing Information
Typical Dose
100-300 mcg before bedtime
Administration
Subcutaneous injection
Cycle Length
Short cycles or as needed
Notes
Evening administration before sleep.
Legal Status
FDA Status
Not FDA-approved
Availability
Research peptide suppliers
WADA Status
Not currently banned
Evidence
Evidence LevelLow
Largest double-blind study (Schneider-Helmert, 1987, PMID: 1299794) concluded DSIP is "not likely to be of major therapeutic benefit." Does NOT affect ACTH/cortisol (PMID: 7777652). Very limited and mostly negative clinical evidence.
Where to Buy
Available from verified suppliers
BiosynTech Research Verified4.5
View Supplier DSIP Economy Vial
LyophilizedPurity: 98%+
COA Available Third-Party TestedIn Stock
NeuroPep Sciences4.6
View Supplier DSIP Sleep Peptide Vial
LyophilizedPurity: 99%+
COA Available Third-Party TestedIn Stock